Pharmacologic class (EPC) · 3 drug pages

Dopaminergic agonist: adverse event reports filed with FDA

6,603 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

6,603
reports across the class: 0% of all reports; 802
reports, 12 months to June 2026: 364 in the 12 months before; 33.2%
marked serious by the reporter: 57.4% across all reports; 3
drugs with a page: brand and generic names counted separately

Dopaminergic agonist is a pharmacologic class (an FDA Established Pharmacologic Class) with 3 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 6,603 adverse event reports received by FDA, 0% of the database, from October 2004 to June 2026.

802 reports arrived in the 12 months to June 2026, up 120% from 364 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 33.2% of the class's reports are marked serious, 5.8% record death among the outcomes and 16.3% record hospitalisation, as reported.

Across the class the reactions recorded most often are nausea (23.2%), somnolence (17.1%) and dizziness (13.1%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
ApokynApomorphine hydrochloride	brand	5,274	188	24.1%	Nausea
Apomorphine hydrochloride	generic	750	46	98.7%	Hypotension
OnapgoApomorphine hydrochloride	brand	579	568	32%	Nausea

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Nauseafeeling sick23.2%1,529
Somnolencedrowsiness17.1%1,132
Dizzinesslight-headedness or unsteadiness13.1%866
Falla fall9.7%641
Vomitingbeing sick6.7%443
Yawning6.2%412
Dyskinesiainvoluntary movements6.1%406
Hypotensionlow blood pressure5.7%374
Fatiguetiredness5.5%366
Hallucinationseeing or hearing things that are not there5.4%359
Drug ineffectivethe medicine did not work as expected5.3%349
Blood pressure decreaseda low blood pressure reading5%330
Hyperhidrosisexcessive sweating4.5%294
Feeling abnormalfeeling odd or not right3.6%236
Headachehead pain3.4%224
Malaisegeneral feeling of being unwell3.3%221
Deaththe patient died; cause not stated by this term3.2%210
Tremorshaking3.1%206
Astheniaweakness or lack of energy3.1%202
Gait disturbancedifficulty walking3%196
Injection site bruisingbruising where the injection was given2.8%188
Injection site erythemaredness where the injection was given2.7%181
Confusional stateconfusion2.7%176
Rhinorrhoeaa runny nose2.3%153
Dyspnoeashortness of breath2.2%146

Solid bar: share of all class reports. Hollow bar: the median share across the 3 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death5.8%382

Life-threatening0.8%55

Hospitalisation (initial or prolonged)16.3%1,078

Disability0.5%35

Congenital anomaly0%0

Other serious15.8%1,046

Not serious66.8%4,409

Patient age

Under 20%0

2 to 110%0

12 to 170%0

18 to 441.5%97

45 to 6421.4%1,415

65 to 7430.8%2,037

75 and over25.9%1,712

Age not given20.3%1,342

Who reported

Physician3.6%238

Pharmacist2.1%139

Other health professional22%1,453

Lawyer0%2

Consumer or non-health professional67.9%4,486

Not given4.3%285

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Dopaminergic agonist reports

Which drugs are in the Dopaminergic agonist class on this site?

Apokyn, Apomorphine hydrochloride and Onapgo. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

6,603 reports through June 2026, 802 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

nausea (23.2%), somnolence (17.1%), dizziness (13.1%), fall (9.7%) and vomiting (6.7%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.